Literature DB >> 31482488

Role of meprin metalloproteases in metastasis and tumor microenvironment.

Florian Peters1, Christoph Becker-Pauly2.   

Abstract

A crucial step for tumor cell extravasation and metastasis is the migration through the extracellular matrix, which requires proteolytic activity. Hence, proteases, particularly matrix metalloproteases (MMPs), have been discussed as therapeutic targets and their inhibition should diminish tumor growth and metastasis. The metalloproteases meprin α and meprin β are highly abundant on intestinal enterocytes and their expression was associated with different stages of colorectal cancer. Due to their ability to cleave extracellular matrix (ECM) components, they were suggested as pro-tumorigenic enzymes. Additionally, both meprins were shown to have pro-inflammatory activity by cleaving cytokines and their receptors, which correlates with chronic intestinal inflammation and associated conditions. On the other hand, meprin β was identified as an essential enzyme for the detachment and renewal of the intestinal mucus, important to prevent bacterial overgrowth and infection. Considering this, it is hard to estimate whether high activity of meprins is generally detrimental or if these enzymes have also protective functions in certain cancer types. For instance, for colorectal cancer, patients with high meprin β expression in tumor tissue exhibit a better survival prognosis, which is completely different to prostate cancer. This demonstrates that the very same enzyme may have contrary effects on tumor initiation and growth, depending on its tissue and subcellular localization. Hence, precise knowledge about proteolytic enzymes is required to design the most efficient therapeutic options for cancer treatment. In this review, we summarize the current findings on meprins' functions, expression, and cancer-associated variants with possible implications for tumor progression and metastasis.

Entities:  

Keywords:  ADAM; Astacin; Ectodomain shedding; Inhibition; Meprin; Metalloprotease

Mesh:

Substances:

Year:  2019        PMID: 31482488     DOI: 10.1007/s10555-019-09805-5

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  4 in total

1.  Helical ultrastructure of the metalloprotease meprin α in complex with a small molecule inhibitor.

Authors:  Charles Bayly-Jones; Christopher J Lupton; Claudia Fritz; Hariprasad Venugopal; Daniel Ramsbeck; Michael Wermann; Christian Jäger; Alex de Marco; Stephan Schilling; Dagmar Schlenzig; James C Whisstock
Journal:  Nat Commun       Date:  2022-10-19       Impact factor: 17.694

2.  Discovery and Optimization of Selective Inhibitors of Meprin α (Part II).

Authors:  Chao Wang; Juan Diez; Hajeung Park; Timothy P Spicer; Louis D Scampavia; Christoph Becker-Pauly; Gregg B Fields; Dmitriy Minond; Thomas D Bannister
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-27

3.  Discovery and Optimization of Selective Inhibitors of Meprin α (Part I).

Authors:  Shurong Hou; Juan Diez; Chao Wang; Christoph Becker-Pauly; Gregg B Fields; Thomas Bannister; Timothy P Spicer; Louis D Scampavia; Dmitriy Minond
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-28

4.  Ginsenoside Rg3 Inhibits the Growth of Osteosarcoma and Attenuates Metastasis through the Wnt/β-Catenin and EMT Signaling Pathway.

Authors:  Xiaohan Mao; Yaqian Jin; Tianyu Feng; Hao Wang; Dan Liu; Zhangxu Zhou; Qi Yan; Huini Yang; Jieru Yang; Jing Yang; Yan Ye; Yuxi Su; Guowei Zuo
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-11       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.